Improved Treatment of Wet Macular Degeneration

Blog vol 2. 48  Improved treatment of Wet Macular Degeneration


The macula is the center of your vision at the back of the eye. Macular degeneration is a largely hereditary condition associated with aging. There are two kinds: dry and wet.


Wet macular degeneration is when the choroidal vessels near the macula start to leak and the eye starts to form new vessels to compensate, the result, if untreated, is very leaky new vessels and permanent scarring.  This used to mean devastating vision loss.


Before the 1990’s this condition was treated with laser and with some improvements, with visudyne and lasers. Then along came a class of drug that works against this new vessel growth and subsequent scarring.


Today, this is the gold standard for treating wet macular degeneration. Drugs like Lucentis or a more recent development, Eylea, are injected into the vitreous of the eye. The first few treatments are monthly, and then if results are good, the injection interval gets extended to as much as 3 months.  Drawbacks are the risk of infection and the possibility of endophthalmitis (inflammation of the inside of the eye), as well as the general unpleasantness of the treatment. 


A reduction in the number of injections necessary would be good. 


A company called Genentech has developed a new drug that is extending this treatment interval. It is called faricimab, and goes by the trade name Vabysmo. The secret in its extensions is its dual action. Unlike its predecessors, that only neutralize the vascular endothelial growth factor-A , faricimab has a complimentary action that neutralizes angiopoietin-2 which also helps to produce these new “leaky” vessels. The additive effect of these two functions equates to less injections. (Read more here).


This is promising for patients and for the health system, making it possible to extend the interval between treatments to at least 4 months. 


New methods of delivery are being developed for a current treatment drug, Lucentis. It is called Susvimo by Roche, and uses an implant that releases the drug slowly so that treatments can be done every six months. Down the road, the use of Vabysmo with an implant may get us to an annual treatment. It is all very exciting.  



til next week,

 

 


the good doctor, Dr. Mark Germain, Burlington optometrist  


The good doctor take a deeper look at how gut health is connected to eye tissues.
By Dr. Mark Germain April 29, 2026
Blog vol 6.40. The Gut and the Eyes. One of my biggest jobs is to keep abreast of new research and advances in eye health. Most recently, we have seen new stem cell research, gene therapies, as well as new drugs for dry and wet macular degeneration. In January of this year, there was an article in the journal, Cell Death and Disease, that looked at cell apoptosis, specifically with the photoreceptors of the eye. (Read the article here ). Apoptosis is the genetic programming of deliberate and constructive cell death, allowing for the maintenance of healthy structures and systems in the body. Some estimates have the body replacing 50 to 70 billion cells daily by this process. Necrosis, on the other hand, is unplanned cell death caused by injury, toxins, or other negative outside factors; this causes inflammation and disrupts the body’s balance of things. There are stressors that speed up cell turnover. The study looked at photoreceptors in the retina and were able to demonstrate cellular recovery, even in late stages of apoptosis, recovery not breakdown. When certain stressors were reduced, by working with the mitochondria, there was recovery of the photoreceptor cells. How? Mitophagy, the mitochondria’s own process of programmed breaking down and then repurposing the recycled components for new ones. This mitochondrial repair helps to reverse the sequence of apoptosis for the photoreceptors. Mitochondria, how cool. How is this helpful for our eyes? Conditions like retinitis pigmentosa or macular degeneration directly involve the photoreceptors and may be slowed or reversed by helping the mitochondria. So, let’s take care of those mitochondria. There is some evidence for nutritional support for the mitochondrial system. The nutrient, Urolithin A (UA), which is a compound made in our gut from fiber found in pomegranates, berries, and nuts is the only clinically proven substance known to trigger mitophagy, made in the gut no less. Vitamin B3 is critical for mitochondria function, however vitamin B3 based supplements are still to be clinically tested for their support of cell recovery. Nutrients Coenzyme Q10 and L-carnitine are known to help the mitochondria generate energy, and interestingly, infrared light therapy has also been shown to benefit mitochondrial function. Again, food for thought. The gut and its function needs a lot of research. How do probiotics and nutrient precursors affect eye tissues? It is so interesting that the gut can be a factor in eye health. Maybe adding Urolithin A as a supplement is wise, along with the antioxidants in Lutein and Zeaxanthin we use to combat photoreceptor degeneration. Will keep you posted on any new developments.  The good doctor
By Dr. Mark Germain April 16, 2026
The good doctor focuses in on visual processing. Why do we miss things that are right in front of our eyes?
By Dr. Mark Germain April 10, 2026
The good doctor discusses the Artemis II mission, space travels affects on the eyes, and "the dark side of the moon"
By Dr. Mark Germain April 3, 2026
The good doctor discusses exciting new and emerging options to treat nystagmus.
By Dr. Mark Germain March 27, 2026
The good doctor reflects on The Country of the Blind, a book by Andrew Leland which gives insight into the experience of vision loss.
By Dr. Mark Germain March 19, 2026
This week's blog focuses on the newest version of the Neurolens - a lens with technology that can provide relief for headaches, neck pain, and eye strain caused by trigeminal dysphoria.
More Posts